Reistone Biopharma Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
220
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$100M
- Investors
-
4
Reistone Biopharma General Information
Description
Developer of small-molecule drugs designed for the treatment of autoimmune and inflammatory diseases. The company offers selective JAK1 inhibitors, BTK inhibitors, and DPP-1 inhibitors, thereby providing patients and healthcare providers with specialized hardware and therapeutic software for managing chronic conditions such as atopic dermatitis, ulcerative colitis, and Crohn's disease.
Contact Information
Website
www.reistonebio.com(Operating Subsidiary)
Corporate Office
- Number 1288 Haike Road, Pudong New Area
- Shanghai, 200120
- China
Corporate Office
- Number 1288 Haike Road, Pudong New Area
- Shanghai, 200120
- China
Reistone Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 09-May-2022 | $100M | Completed | Generating Revenue | ||
| 1. Merger/Acquisition | 03-Nov-2019 | Completed | Generating Revenue |
Reistone Biopharma Comparisons
Industry
Financing
Details
Reistone Biopharma Competitors (1)
One of Reistone Biopharma’s competitors is Equillium, a Formerly VC-backed company based in La Jolla, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Equillium | Formerly VC-backed | La Jolla, CA |
Reistone Biopharma Patents
Reistone Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024174994-A1 | Anti-il-18rβ antibody, antigen-binding fragment thereof and medical use thereof | Inactive | 20-Feb-2023 | ||
| EP-4663192-A1 | Pharmaceutical composition for local administration, preparation method therefor, and use thereof | Pending | 07-Feb-2023 | ||
| EP-4663192-A4 | Pharmaceutical composition for local administration, preparation method therefor, and use thereof | Pending | 07-Feb-2023 | ||
| US-20260232671-A1 | Pharmaceutical composition for local administration, preparation method therefor, and use thereof | Pending | 07-Feb-2023 | ||
| WO-2024165036-A1 | Pharmaceutical composition for local administration, preparation method therefor, and use thereof | Inactive | 07-Feb-2023 | A61K9/0014 |
Reistone Biopharma Signals
Reistone Biopharma FAQs
-
When was Reistone Biopharma founded?
Reistone Biopharma was founded in 2018.
-
Where is Reistone Biopharma headquartered?
Reistone Biopharma is headquartered in Shanghai, China.
-
What is the size of Reistone Biopharma?
Reistone Biopharma has 220 total employees.
-
What industry is Reistone Biopharma in?
Reistone Biopharma’s primary industry is Drug Discovery.
-
Is Reistone Biopharma a private or public company?
Reistone Biopharma is a Private company.
-
What is Reistone Biopharma’s current revenue?
The current revenue for Reistone Biopharma is .
-
How much funding has Reistone Biopharma raised over time?
Reistone Biopharma has raised $100M.
-
Who are Reistone Biopharma’s competitors?
Equillium is a competitor of Reistone Biopharma.
-
When was Reistone Biopharma acquired?
Reistone Biopharma was acquired on 09-May-2022.
-
Who acquired Reistone Biopharma?
Reistone Biopharma was acquired by Shanghai Shengdi Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process